|Dr. Peter A. Altman||CEO, Pres & Director||362.7k||N/A||1967|
|Mr. David McClung||Chief Financial Officer||302.25k||N/A||1963|
|Dr. Eric Henricus J. Duckers||Chief Medical Officer||350k||N/A||1968|
|Mr. Phil Pesta||VP of Operations||N/A||N/A||1966|
|Dr. Ian McNiece Ph.D.||Chief Scientific Officer||N/A||N/A||1954|
|Mr. Edward M. Gillis||Sr. VP of Devices||N/A||N/A||1962|
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
BioCardia, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.